IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

Ong, L.S.; Chyan Lee, Wee; Ma, Shijun; Oguz, Gokce; Niu, Zhitong; Yi, Bao; Yusuf, Mubaraka; Leng Lee, Puay; Yuan Goh, Jian; Wang, Panpan; Su Mei Yong, Kylie; Chen, Qingfeng; Wang, Wenyu; Ramasamy, Adaikalavan; S.�B. Hoon, Dave; J. Ditzel, Henrik; Yu Tan, Ern; Chin Lee, Soo; Yu, Qiang

doi:10.1073/pnas.2201376119

Public

IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer

Published in Proceedings of the National Academy of Sciences • Jul 25, 2022

Authors:

L.S. Ong

Wee Chyan Lee

Shijun Ma

Abstract

Relapse to anti-HER2 monoclonal antibody (mAb) therapies, such as trastuzumab in HER2 + breast cancer (BC), is associated with residual disease progression due to resistance to therapy. Here, we identify interferon-γ inducible protein 16 (IFI16)-dependent STING signaling as a significant determinant...

Subject

Trastuzumab

Cancer research

EZH2

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!